Key Highlights
- Option Care Health (NASDAQ:OPCH) traded at USD 31.32 on October 28, 2026, up 35.74% over one month, up 0.08% over one week, up 36.33% over three months and down 1.80% year to date, per published market data.
- Clayton, Dubilier & Rice and McKesson (NYSE:MCK) agreed on October 5, 2026 to buy Option Care Health for USD 32.05 in cash per share, an enterprise value of about USD 5.8 billion and a 37% premium.
- Option Care Health (NASDAQ:OPCH) at USD 31.32 trades about 2.3% below the offer, simple arithmetic, and the offer is only about 0.5% above the start-of-year price implied by the 1.80% year to date decline.
- Closing is expected in the first half of 2027 after shareholder approval and regulatory clearances, and the company withdrew its financial guidance and will hold no third quarter call.
The Buyout
On October 5, 2026, Option Care Health (NASDAQ:OPCH) agreed to be acquired by Clayton, Dubilier & Rice and McKesson for USD 32.05 per share in cash, an enterprise value of about USD 5.8 billion. The price is about a 37% premium to the October 5 close, which implies a close near USD 23.39, simple arithmetic. CD&R will initially own about 51% and McKesson will invest about USD 1.4 billion for about 49%, with a framework for McKesson to acquire CD&R's interest later. The board approved the deal unanimously, and management stays in place. Option Care Health provides home and alternate-site infusion therapy, and a buyer with distribution scale may see strategic fit.
Timing and Reaction
The shares rose about 32.88% on the first trading day after the announcement, and the stock has gained 35.74% over a month, from an implied price near USD 23.07. Closing needs the approval of shareholders and regulators and is expected in the first half of 2027, after which the company will stop trading on Nasdaq. Because the offer is cash, the shares now behave like a merger-arbitrage position, with a one-week move of only 0.08%. The company reports third quarter results on November 4, 2026 without an earnings call and has withdrawn guidance. Merger arbitrage funds buy at a small discount and collect the spread at closing, which anchors the price near the offer.
Risks and What to Watch
If the deal fails, the premium would disappear and the stock could return toward its pre-announcement level, simple arithmetic on the offer premium. Regulatory review of a combination involving a large drug distributor and a home infusion provider could take time, and the 2.3% spread reflects that wait. The offer is close to the price at the start of the year, so holders who bought earlier may feel the price is a fair exit rather than a bargain. Watch the proxy statement and the November 4 report. This is not advice. The CD&R and McKesson structure also adds complexity, because McKesson's later option to acquire CD&R's stake depends on conditions and approvals.
Where Things Stand
The answer is that the October 5, 2026 buyout agreement explains the month. CD&R and McKesson agreed to pay USD 32.05 per share in cash, and Option Care Health (NASDAQ:OPCH) now trades about 2.3% below that price. The offer is close to the start-of-year price, so the rally restored value rather than creating it. Shareholder and regulatory approvals through the first half of 2027 are the remaining steps.






Please wait processing your request...